This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ruokolainen, H. Articles by Turpeenniemi-Hujanen, T. Search for Related Content PubMed PubMed Citation Articles by Ruokolainen, H. Articles by Turpeenniemi-Hujanen, T.

Tissue Inhibitor of Matrix Metalloproteinase-1 Is Prognostic in Head and Neck Squamous Cell Carcinoma: Comparison of the Circulating and Tissue Immunoreactive Protein

Authors' Affiliations: Departments of ¹ Oncology, and Radiotherapy, and ² Pathology, University of Oulu and Oulu University Hospital, Oulu, Finland

Requests for reprints: Taina Turpeenniemi-Hujanen, Department of Oncology and Radiotherapy, Oulu University Hospital, P.O. Box 22, FIN-90211 Oulu, Finland. Fax: 358-8-3156449; E-mail: turpeenniemi.hujanen.ppshp.fi.

Purpose: Tissue inhibitors of metalloproteinases (TIMP) are capable of inhibiting the matrix metalloproteinases, but they also possess other biological functions. Little is known about the role of TIMP-1 in the progression and spreading of cancer cells among patients with head and neck squamous cell carcinoma (HNSCC). In this study, the pretreatment serum levels of TIMP-1 or the overexpression of TIMP-1 immunoreactive protein in the primary tumor was correlated to the clinical course in patients with HNSCC.

Experimental Design: The TIMP-1 immunoreactive protein was studied in 74 cases representing HNSCC. The tissue immunoreactive protein was evaluated from paraffin-embedded tumor sections in 68 cases using immunohistologic staining with a specific antibody, and in 68 cases the pretreatment serum levels of TIMP-1 were quantitatively measured by ELISA assay. The results were compared with the clinicopathologic factors of the disease and the patients' outcome.

Results: A positive correlation was found between the size of the primary tumor (T) and the circulating TIMP-1 level (P = 0.021) or the positive immunoreaction of TIMP-1 in tumor (P = 0.039). The 5-year cause-specific survival was significantly lower in patients presenting with a high serum TIMP-1 level than in those with a low level of TIMP-1 (38% versus 64%, P = 0.034). They also had an unfavorable 5-year relapse-free survival rate (37% versus 56%, respectively). Similarly, the expression of TIMP-1 in tumor was prognostic for shortened survival, the 5-year cumulative relapse-free survival being 42% in patients with a TIMP-1–positive tumor versus 75% in cases with a negative tumor (P = 0.035). Tissue TIMP-1 positivity also seemed associated to the cause-specific survival (P = 0.075) and to be connected with later lymph node or hematogenic relapses.

Conclusions: This study shows for the first time that both circulating and tissue TIMP-1 immunoreactive protein predicts the clinical course and dissemination in HNSCC, suggesting that TIMP-1 might be related to both tumor growth and metastasis in HNSCC.

Key Words: TIMP-1 • squamous cell carcinoma • prognostic factor • metastasis • survival • serum marker

This article has been cited by other articles:

				J. Verstappen and J.W. Von den Hoff Tissue Inhibitors of Metalloproteinases (TIMPs): Their Biological Functions and Involvement in Oral Disease. J. Dent. Res., December 1, 2006; 85(12): 1074 - 1084. [Abstract] [Full Text] [PDF]

				K. Jung Impact of Blood Sampling on Circulating Tissue Inhibitors of Metalloproteinases Clin. Cancer Res., April 15, 2006; 12(8): 2648 - 2648. [Full Text] [PDF]

				H. Ruokolainen and T. Turpeenniemi-Hujanen Reply to the Letter to the Editor from Jung Clin. Cancer Res., April 15, 2006; 12(8): 2648 - 2648. [Full Text] [PDF]